Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

INTRODUCTION: Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose‐intense chemotherapy regimens, such as CODOX‐M/IVAC. While rituximab has increased survival rates for most forms of high‐grade B‐cell lymphoma, there has previously been hesitancy ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Elizabeth H., Burton, Catherine, Kirkwood, Amy A., Barrans, Sharon, Lawrie, Anthony, Rule, Simon, Patmore, Russell, Pettengell, Ruth, Ardeshna, Kirit M., Montoto, Silvia, Paneesha, Shankara, Clifton‐Hadley, Laura, Linch, David C., McMillan, Andrew K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176097/
https://www.ncbi.nlm.nih.gov/pubmed/35847742
http://dx.doi.org/10.1002/jha2.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176097/
https://www.ncbi.nlm.nih.gov/pubmed/35847742
http://dx.doi.org/10.1002/jha2.3

Ejemplares similares